Advertisement
What really powers the cloud? Behind every Google search, A...
A lot of what defines a home isn’t visible at handover. I...
Private equity has played a significant role in shaping Indi...
Luxury real estate is one of the most talked-about segments ...
Airports play a much bigger role than just enabling travel -...
Mumbai-based nutrition company TruNativ has secured approximately USD 30 million in a Series B funding round led by global healthcare investor OrbiMed. The funding comprises a combination of primary capital infusion and secondary share sales by early investors. Founded in 2019, TruNativ plans to utilise the proceeds to strengthen its nationwide distribution network across direct-to-consumer, quick commerce, modern trade, pharmacy and retail channels, while expanding its B2B2C ingredients business. The investment reflects growing investor interest in India’s preventive healthcare and nutrition sector, where consumer demand for science-backed and clean-label products continues to rise. OrbiMed representatives will also join the company’s board as part of the transaction.
TruNativ, a Mumbai-based nutrition company focused on science-backed consumer health products, has raised approximately USD 30 million in a Series B funding round led by healthcare-focused investment firm OrbiMed.
The funding round, announced on June 17, comprises a mix of primary investment into the company and secondary share sales by existing early-stage investors. The transaction marks a significant capital raise for TruNativ as it seeks to expand its presence across India's growing nutrition and preventive healthcare market.
The company said the newly raised capital will be deployed towards expanding its distribution network across multiple channels, including direct-to-consumer platforms, quick commerce, modern trade, pharmacies and traditional retail formats. TruNativ also plans to accelerate the growth of its B2B2C ingredients business, which currently supplies nutrition-focused solutions to several consumer brands in India.
Founded in Mumbai in 2019 by mother-son duo Mamta Malhotra and Pranav Malhotra, TruNativ began operations with a sugar replacement product before expanding into a broader nutrition platform. Its portfolio now spans multiple categories including sugar alternatives, protein supplements, gut health products and wellness-focused offerings.
According to the company, it currently holds a majority share of the sugar replacement segment on leading quick commerce platforms and ranks first in the dietary fibre and sweetener categories on Amazon India.
Pranav Malhotra, Co-Founder and Chief Executive Officer of TruNativ, stated that India is witnessing a fundamental shift towards preventive nutrition and healthier dietary habits. He said the company was established to address longstanding gaps in access to nutrition products and that OrbiMed’s investment underscores the growing recognition of preventive nutrition as an important component of healthcare. He added that the company intends to contribute to positioning India as a centre for nutrition innovation.
Commenting on the investment, Dr Sunny Sharma, Senior Managing Director at OrbiMed Asia, said the investment firm shares the company’s objective of improving nutrition access and supporting healthier lifestyle choices. He noted that OrbiMed sees an opportunity to support TruNativ as it expands its consumer health business.
As part of the investment, Dr Sharma and Sumona Chakraborty from OrbiMed will join TruNativ’s board, providing strategic oversight as the company enters its next phase of growth.
The investment comes amid rising consumer awareness of preventive healthcare, nutrition and wellness across India. Industry participants have reported growing demand for clean-label products, functional nutrition solutions and science-backed health supplements as consumers place greater emphasis on long-term health management.
OrbiMed, one of the world's largest healthcare-focused investment firms, manages approximately USD 20 billion in assets across public equities, private equity, venture capital and royalty strategies. The firm invests globally across healthcare sectors including biotechnology, pharmaceuticals, medical devices and healthcare services.
PwC acted as the exclusive financial adviser to TruNativ for the transaction.
With the latest capital infusion, TruNativ aims to strengthen its market position across high-growth nutrition categories while expanding distribution reach and deepening its engagement with both consumers and business partners across India’s evolving healthcare and wellness ecosystem.
Advertisement
Facebook
Whatsapp
